AKBLF
ALK-Abelló A/S
$33.70
+0.00% 2026-10-19
Healthcare
AKBLFSPY
1W
+0.0%
1M
+3.8%
3M
-11.1%
6M
+7.5%
YTD
-1.8%
1Y
+9.6%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsPhase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy
GlobeNewswire · Oct 19
Will Raised 2026 Guidance Change ALK Abelló Stock Narrative
Simply Wall St. · Oct 16
BSACI 2026: New preference and ease-of-use data comparing EURneffy® nasal adrenaline spray and adrenaline auto-injector trainer devices
GlobeNewswire · Oct 12
ALK upgrades its full-year outlook on strong tablet sales
GlobeNewswire · Oct 07
ALK-Abelló Pharmaceuticals Inc Announces Positive Funding Recommendation from Canada's Drug Agency for neffy® for the Emergency Treatment of Allergic Reactions (Anaphylaxis)
CNW Group · Oct 01
Key stats
Market cap$7.5B
P/E (trailing)35.5
P/E (forward)42.1
52-week range30.50 – 40.65
Revenue growth (YoY, latest qtr)+17.6%
Dividend yield0.73%
Analyst consensusNone
Mean price target–
Valuation and fundamentals
Valuation & fundamentals
No SEC filings found for this ticker (foreign filer, ETF or fund).
Earnings
Next report: 2026-11-17 · during market · EPS est 1.70
No EPS history available.
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.8B | +17.6% |
| 2026-03-31 | $1.8B | – |
| 2025-12-31 | $1.7B | – |
| 2025-09-30 | $1.5B | – |
| 2025-06-30 | $1.5B | – |
Recent dividends
2026-03-17: $0.240 · 2017-03-16: $0.038 · 2016-03-11: $0.038 · 2015-03-13: $0.038 · 2014-03-13: $0.038 · 2013-03-13: $0.038 · 2012-03-28: $0.038 · 2011-04-04: $0.038
Stats refreshed 2026-10-20 18:08:57 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.